Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 17/2023

05.09.2023 | Research

Correlation between androgen and estrogen receptor expression and clinicopathologic features in carcinoma urinary bladder

verfasst von: Nikita Shrivastava, Rahul Jena, Gautam Ram Choudhary, Priyank Bhargava, Vikarn Vishwajeet, Poonam Elhence, Mahendra Singh, Deepak Prakash Bhirud, Arjun Singh Sandhu

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 17/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The molecular mapping of cancers by the Cancer Genome Atlas Project has accelerated the quest for new therapeutic targets for urinary bladder cancer, including sex steroid receptors. Previous studies have demonstrated conflicting results on their relationship with bladder cancer, and there is sparse data on their expression in the Indian population. The aim of our study is to examine the expression of androgen receptors (AR) and estrogen receptors (ERα and ERβ) in patients with bladder cancer and their correlation with clinicopathologic features.

Materials and methods

In this retrospective cohort study, a total of 132 patients, who were surgically managed for urinary bladder mass by transurethral resection or radical cystectomy in our institute, with transitional cell carcinoma on histopathology and with at least two years of follow-up were included. Their demographic and treatment details were obtained, histopathology blocks were retrieved and immunohistochemical staining for androgen and estrogen receptors was performed. Then, the relationship between their expression and clinicopathologic features was studied.

Results

A total of 3.79% of patients showed estrogen receptor alpha positivity, 51.52% estrogen receptor beta positivity and 63.64% androgen receptor positivity. No statistically significant correlation was found between age of patients (p = 0.75/0.52/0.87), tumour stage and grade (0.71/0.3/0.21), pathological variant (p = 1/0.58/0.38) and overall survival (p = 0.70/0.052/0.45 for NMIBC and p = 0.82/0.36/0.22) and estrogen receptor alpha, estrogen receptor beta and androgen receptor-positive status, respectively. Estrogen receptor beta positivity was significantly higher in patients with unifocal (p = 0.015) and small tumours (< 5 cm) (p = 0.03), and its expression was associated with better disease-free survival (DFS) (p = 0.046) in patients of non-muscle invasive bladder cancer (NMIBC).

Conclusion

Our study has the largest sample size conducted on Indian population with results differing from previous studies conducted on western population. Estrogen receptor beta expression was significantly associated with small unifocal tumours and better DFS. Estrogen receptor alpha and androgen receptor expression were not found to be associated with the clinicopathologic features of the study population.
Literatur
Zurück zum Zitat An MH, Kim MS, Kim C, Noh TI, Joo KJ, Lee DH, Yi KH, Kwak JW, Hwang TH, Park RW, Kang SH (2023) Association of 5α-reductase inhibitor prescription with bladder cancer progression in males in South Korea. JAMA Netw Open 6(5):e2313667CrossRefPubMedPubMedCentral An MH, Kim MS, Kim C, Noh TI, Joo KJ, Lee DH, Yi KH, Kwak JW, Hwang TH, Park RW, Kang SH (2023) Association of 5α-reductase inhibitor prescription with bladder cancer progression in males in South Korea. JAMA Netw Open 6(5):e2313667CrossRefPubMedPubMedCentral
Zurück zum Zitat Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL et al (2022) European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81(1):75–94CrossRefPubMed Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL et al (2022) European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81(1):75–94CrossRefPubMed
Zurück zum Zitat Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026CrossRefPubMedPubMedCentral Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026CrossRefPubMedPubMedCentral
Zurück zum Zitat Bolenz C, Lotan Y, Ashfaq R, Shariat SF (2009) Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol 56(6):1093–1095CrossRefPubMed Bolenz C, Lotan Y, Ashfaq R, Shariat SF (2009) Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol 56(6):1093–1095CrossRefPubMed
Zurück zum Zitat Boorjian S, Ugras S, Mongan NP et al (2004) Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 64(2):383–388CrossRefPubMed Boorjian S, Ugras S, Mongan NP et al (2004) Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 64(2):383–388CrossRefPubMed
Zurück zum Zitat Deltourbe L, Lacerda Mariano L, Hreha TN, Hunstad DA, Ingersoll MA (2022) The impact of biological sex on diseases of the urinary tract. Mucosal Immunol 15(5):857–866CrossRefPubMedPubMedCentral Deltourbe L, Lacerda Mariano L, Hreha TN, Hunstad DA, Ingersoll MA (2022) The impact of biological sex on diseases of the urinary tract. Mucosal Immunol 15(5):857–866CrossRefPubMedPubMedCentral
Zurück zum Zitat Gupta P, Jain M, Kapoor R, Muruganandham K, Srivastava A, Mandhani A (2009) Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J Urol 25:207–210CrossRefPubMedPubMedCentral Gupta P, Jain M, Kapoor R, Muruganandham K, Srivastava A, Mandhani A (2009) Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J Urol 25:207–210CrossRefPubMedPubMedCentral
Zurück zum Zitat Gupta S, Dhillon J, Magliocco AM, Puskas J, Caceres G, Masawi F, Doronin Y, Zhang J (2019) Results from a phase i/ib trial of enzalutamide and gemcitabine and cisplatin in metastatic bladder cancer (mbc). J Clin Oncol 37:471CrossRef Gupta S, Dhillon J, Magliocco AM, Puskas J, Caceres G, Masawi F, Doronin Y, Zhang J (2019) Results from a phase i/ib trial of enzalutamide and gemcitabine and cisplatin in metastatic bladder cancer (mbc). J Clin Oncol 37:471CrossRef
Zurück zum Zitat Ide H, Inoue S, Miyamoto H (2017) Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: a meta-analysis of immunohistochemical studies. PLoS ONE 12:e0174746CrossRefPubMedPubMedCentral Ide H, Inoue S, Miyamoto H (2017) Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: a meta-analysis of immunohistochemical studies. PLoS ONE 12:e0174746CrossRefPubMedPubMedCentral
Zurück zum Zitat Mashhadi R, Pourmand G, Kosari F et al (2014) Role of steroid hormone receptors in formation and progression of bladder carcinoma: a case-control study. Urol J 11(6):1968–1973PubMed Mashhadi R, Pourmand G, Kosari F et al (2014) Role of steroid hormone receptors in formation and progression of bladder carcinoma: a case-control study. Urol J 11(6):1968–1973PubMed
Zurück zum Zitat Mir C, Shariat SF, van der Kwast TH et al (2011) Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int 108(1):24–30CrossRefPubMed Mir C, Shariat SF, van der Kwast TH et al (2011) Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int 108(1):24–30CrossRefPubMed
Zurück zum Zitat Miyamoto H, Yao JL, Chaux A et al (2012) Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 109(11):1716–1726CrossRefPubMed Miyamoto H, Yao JL, Chaux A et al (2012) Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 109(11):1716–1726CrossRefPubMed
Zurück zum Zitat Moorthy HK, Prabhu GG, Venugopal P (2020) Clinical and therapeutic implications of sex steroid hormone receptor status in urothelial bladder cancer. Indian J Urol 36:171–178CrossRefPubMedPubMedCentral Moorthy HK, Prabhu GG, Venugopal P (2020) Clinical and therapeutic implications of sex steroid hormone receptor status in urothelial bladder cancer. Indian J Urol 36:171–178CrossRefPubMedPubMedCentral
Zurück zum Zitat Nam JK, Park SW, Lee SD, Chung MK (2014) Prognostic value of sex hormone receptor expression in non-muscle-invasive bladder cancer. Yonsei Med J 55:1214–1221CrossRefPubMedPubMedCentral Nam JK, Park SW, Lee SD, Chung MK (2014) Prognostic value of sex hormone receptor expression in non-muscle-invasive bladder cancer. Yonsei Med J 55:1214–1221CrossRefPubMedPubMedCentral
Zurück zum Zitat Pachauri A, Pahwa HS, Kumar A (2017) Evaluation of androgen receptor and HER2/neu receptor in tumor tissue of transitional cell carcinoma of urinary bladder and normal bladder mucosa. Arch Int Surg 7:115–120CrossRef Pachauri A, Pahwa HS, Kumar A (2017) Evaluation of androgen receptor and HER2/neu receptor in tumor tissue of transitional cell carcinoma of urinary bladder and normal bladder mucosa. Arch Int Surg 7:115–120CrossRef
Zurück zum Zitat Rodriguez-Vida A, Lerner SP, Bellmunt J (2018) The cancer genome atlas project in bladder cancer. Cancer Treat Res 175:259–271CrossRefPubMed Rodriguez-Vida A, Lerner SP, Bellmunt J (2018) The cancer genome atlas project in bladder cancer. Cancer Treat Res 175:259–271CrossRefPubMed
Zurück zum Zitat Sankhwar M, Sankhwar SN, Bansal SK, Gupta G, Rajender S (2016) Polymorphisms in the XPC gene affect urinary bladder cancer risk: a case-control study, meta-analyses and trial sequential analyses. Sci Rep 1(6):27018CrossRef Sankhwar M, Sankhwar SN, Bansal SK, Gupta G, Rajender S (2016) Polymorphisms in the XPC gene affect urinary bladder cancer risk: a case-control study, meta-analyses and trial sequential analyses. Sci Rep 1(6):27018CrossRef
Zurück zum Zitat Scosyrev E, Trivedi D, Messing E (2010) Female bladder cancer: incidence, treatment, and outcome. Curr Opin Urol 20:404–408CrossRefPubMed Scosyrev E, Trivedi D, Messing E (2010) Female bladder cancer: incidence, treatment, and outcome. Curr Opin Urol 20:404–408CrossRefPubMed
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249CrossRefPubMed
Zurück zum Zitat Tuygun C, Kankaya D, Imamoglu A et al (2011) Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 29(1):43–51CrossRefPubMed Tuygun C, Kankaya D, Imamoglu A et al (2011) Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 29(1):43–51CrossRefPubMed
Zurück zum Zitat Wagih M, Kamel M (2020) Evaluation of androgen receptor status in urothelial carcinoma of the urinary bladder in Egyptian patients: an immunohistochemical study. Afr J Urol 26(1):1CrossRef Wagih M, Kamel M (2020) Evaluation of androgen receptor status in urothelial carcinoma of the urinary bladder in Egyptian patients: an immunohistochemical study. Afr J Urol 26(1):1CrossRef
Metadaten
Titel
Correlation between androgen and estrogen receptor expression and clinicopathologic features in carcinoma urinary bladder
verfasst von
Nikita Shrivastava
Rahul Jena
Gautam Ram Choudhary
Priyank Bhargava
Vikarn Vishwajeet
Poonam Elhence
Mahendra Singh
Deepak Prakash Bhirud
Arjun Singh Sandhu
Publikationsdatum
05.09.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 17/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-023-05348-z

Weitere Artikel der Ausgabe 17/2023

Journal of Cancer Research and Clinical Oncology 17/2023 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.